Trastuzumab—mechanism of action and use in clinical practice

CA Hudis - New England journal of medicine, 2007 - Mass Medical Soc
CA Hudis
New England journal of medicine, 2007Mass Medical Soc
Overexpression of human epidermal growth factor receptor type 2 (HER2) in breast cancer
is associated with decreased overall survival. Trastuzumab, a humanized monoclonal
antibody that targets HER2, is approved by the Food and Drug Administration for patients
with invasive breast cancers that overexpress HER2. This review considers the mechanism
of action and the use of this agent.
Overexpression of human epidermal growth factor receptor type 2 (HER2) in breast cancer is associated with decreased overall survival. Trastuzumab, a humanized monoclonal antibody that targets HER2, is approved by the Food and Drug Administration for patients with invasive breast cancers that overexpress HER2. This review considers the mechanism of action and the use of this agent.
The New England Journal Of Medicine